Hemovigilance
Hemovigilance
An Effective Tool for Improving Transfusion Safety

EDITED BY

René R.P. De Vries MD
Past President of the International Haemovigilance Network (IHN) and Head of the Blood Transfusion Service, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands

Jean-Claude Faber MD
President of the International Haemovigilance Network (IHN) and retired as Medical Director, Blood Transfusion Service of the Luxembourg Red Cross, Luxembourg
Contents

List of Contributors, viii
Foreword, xii

Part 1 General Introduction

1 Introduction,  3
René R.P. de Vries

2 Hemovigilance: A Quality Tool for the Blood Transfusion Chain,  5
René R.P. de Vries

3 Concepts and Models,  12
René R.P. de Vries and Jean-Claude Faber

Part 2 Hemovigilance of the Blood Transfusion Chain (Blood Establishment and Hospital)

Section 2.1: Setting up a Hemovigilance System

4 Setting Up or Consolidating a System for Donor Hemovigilance at the Level of a Blood Establishment,  21
Johanna Wiersum-Osselton, Wim de Kort, Tanneke Marijt-van der Kreek, and Jeroen de Wit

5 Preparation of Blood Components,  36
Tomislav Vuk

6 Establishment of Hemovigilance for the Testing, Storage, Distribution, Transport, and Issuing of Blood and Blood Components: The Example of Greece,  52
Constantina Politis

7 Medical Decision, Ordering, Administration of Component, and Monitoring of the Patient,  61
Mickey B.C. Koh, Ramir Alcantara, Mark Grumbridge, and Ai Leen Ang

Section 2.2: How the System Works

8 Blood Donation: An Approach to Donor Vigilance,  77
Peter Tommasolo, Madhav Errajuntla, and Hany Kamel

9 Preparation of Blood Components,  99
Erhard Seifried, Reinhard Henschler, Juergen Luhm, Thea Mueller-Kuller, Hans-Ulrich Pfeiffer, Walid Sireis, and Markus M. Mueller
Contents

10 Testing, Issuing, and Transport of Blood Components, 113
   Constantina Politis

11 Clinical Activities: Medical Decision-making, Sampling, Ordering Components, Administration, and Patient Monitoring, 126
   Clare Taylor

Part 3 National or Regional Hemovigilance Systems

12 The French Hemovigilance Network: From the Blood Scandal to Epidemiologic Surveillance of the Transfusion Chain, 147
   Philippe Renaudier

13 The Japanese Hemovigilance System, 159
   Hitoshi Okazaki, Naoko Goto, Shun-ya Momose, Satoru Hino, and Kenji Tadokoro

14 Setting up a National Hemovigilance System: SHOT, 168
   Hannah Cohen and Lorna M. Williamson

15 The Dutch Hemovigilance System: Transfusion Reactions in Patients (TRIP), 180
   Martin R. Schipperus, Johanna Wiersum-Osselton, Pauline Y. Zijlker-Jansen, and Anita J.W. van Tilborgh-de Jong

16 Regulatory, Public Health, and International Aspects of Hemovigilance in Canada, 191
   Peter R. Ganz and Jun Wu

17 Setting up and Implementation of the National Hemovigilance System in Italy, 204
   Giuliano Grazzini and Simonetta Pupella

18 The Australian Hemovigilance System, 209
   Erica M. Wood, Lisa J. Stevenson, Simon A. Brown, and Christopher J. Hogan

19 Biovigilance in the United States, 220
   D. Michael Strong, Barbee Whitaker, Matthew J. Kaehnert, and Jerry A. Holmberg

20 Arab Hemovigilance Network, 226
   Salwa Hindawi, Magdy Elekiaby, and Gamal Gabra

Part 4 Hemovigilance at the International Level

21 Hemovigilance in the European Community, 235
   Jean-Claude Faber

22 International collaboration, 253
   Paul F.W. Strengers

23 Hemovigilance in Developing Countries, 260
   Jean-Claude Faber

Part 5 Achievements

24 Achievements Through Hemovigilance, 281
   Jean-Claude Faber and Fátima Nascimento
Part 6 Developments

25 Vigilance of Alternatives for Blood Components, 305
   Dafydd Thomas

26 Surveillance of Clinical Effectiveness of Transfusion, 322
   Brian McClelland and Katherine Forrester

27 Biovigilance, 326
   Jerry A. Holmberg, Matthew J. Kuehnert, and D. Michael Strong

Appendices

Appendix A Glossary, 343

Appendix B Proposed standard definitions for surveillance of non infectious adverse transfusion reactions, 351

Appendix C Standard for surveillance of complications related to blood donation, 360

Index, 369
List of Contributors

Ramir Alcantara MD
Registrar
Blood Services Group
Health Sciences Authority
Singapore

Ai Leen Ang MD, FRCPath
Consultant
Blood Services Group
Health Sciences Authority
Singapore

Simon A. Brown MBBS, MD, FRCP, FRCPA
Clinical Advisor and Consultant Haematologist
Queensland Blood Management Program & Pathology
Queensland
Brisbane, Australia

Hannah Cohen MD, FRCP, FRPath
Consultant Haematologist and Honorary Senior Lecturer
University College London Hospitals and University College
London
Department of Haematology
London, UK

Magdy Elekiaby MSc, MD
Head of Blood Transfusion Center
Shabrawishi Hospital
Giza, Egypt

Madhav Erraguntla PhD
Senior Research Scientist
Knowledge Based Systems Inc
College Station, TX, USA

Katherine Forrester PhD
Transfusion Researcher
Scottish National Blood Transfusion Service
Edinburgh, UK

Gamal Gabra MD
Transfusion Medicine Consultant
Birmingham Blood Transfusion Center
Birmingham, UK

Peter R. Ganz PhD
Director, Centre for Biologics Evaluation
Health Canada
Ottawa, ON, Canada;
Adjunct Professor
Faculty of Medicine
University of Ottawa
Ottawa, ON, Canada

Naoko Goto MS
Deputy Director
Safety Vigilance Division
Blood Service Headquarters
Japanese Red Cross Society
Tokyo, Japan

Giuliano Grazzini MD, PhD
Director, National Blood Centre
Istituto Superiore di Sanità
Rome, Italy

Mark Grumbridge RGN BSc Dip N
Transfusion Practitioner
Department of Haematology
St George’s Hospital and Medical School
London, UK

Reinhard Henschler MD
Head, Department of Production
Institute for Transfusion Medicine and Immunohaematology
Clinics of the Johann Wolfgang Goethe University
Frankfurt/Main

viii
Salwa Hindawi MD, FRCPath, CTM  
President of Saudi Society of Transfusion Medicine  
ISBT Eastern Mediterranean Regional Director  
Member of WHO Advisory Panel on Blood Safety  
Director of Blood Transfusion Services  
KING Abdulaziz University, Jeddah  
Saudi Arabia

Satoru Hino MPharm  
Deputy Director General  
(General Manufacturing/Distribution Supervisor)  
Blood Service Headquarters  
Japanese Red Cross Society  
Tokyo, Japan

Christopher J. Hogan MBBS, BSc (Hons), FRCPA  
Principal Medical Officer  
National Blood Authority, Canberra;  
Chair, Australian Haemovigilance Advisory Committee  
Canberra, Australia

Jerry A. Holmberg PhD  
Director, Scientific Affairs  
Novartis Vaccines and Diagnostics Inc.  
Emeryville, CA, USA

Hany Kamel MD  
Corporate Medical Director  
Blood Systems Inc.  
Scottsdale, AZ, USA

Mickey B.C. Koh MD, PhD, FRCPA  
Consultant Haematologist  
Director, Stem Cell Transplant Programme  
St George’s Hospital and Medical School  
London, UK;  
Medical Director, Cell Therapy Facility  
Health Sciences Authority  
Singapore;  
Division Director  
Blood Services Group  
Health Sciences Authority  
Singapore

Wim de Kort MD, PhD  
Director, Donor Services  
Sanquin Blood Supply Foundation  
Nijmegen, The Netherlands

Matthew J. Kuehnert MD  
Director, Office of Blood, Organ, and other Tissue Safety  
Division of Healthcare Quality Promotion  
Centers for Disease Control and Prevention (CDC)  
Atlanta, GA, USA

Juergen Luhm PhD  
Quality Manager  
Institute for Transfusion Medicine and Immunohaematology  
Clinics of the Johann Wolfgang Goethe University  
Frankfurt/Main  
German Red Cross Blood Donor Services  
Baden-Wuertemberg-Hessen  
Frankfurt/Main, Germany

Tanneke Marijt-van der Kreek MD  
Chief Donor Physician in Southwestern Region  
Sanquin Blood Supply Foundation  
Rotterdam, The Netherlands

Brian McClelland MD  
Scottish National Blood Transfusion Service  
Edinburgh, UK

Shun-ya Momose BPharm  
Director  
Safety Vigilance Division  
(Safety Management Supervisor)  
Blood Service Headquarters  
Japanese Red Cross Society  
Tokyo, Japan

Markus M. Mueller  
Consultant in Transfusion Medicine  
Department Head of Blood Donation  
Institute for Transfusion Medicine and Immunohaematology  
Clinics of the Johann Wolfgang Goethe University  
Frankfurt/Main  
German Red Cross Blood Donor Services  
Baden-Wuertemberg-Hessen  
Frankfurt/Main, Germany

Thea Mueller-Kuller PhD  
Quality Manager  
Institute for Transfusion Medicine and Immunohaematology  
Clinics of the Johann Wolfgang Goethe University  
Frankfurt/Main  
German Red Cross Blood Donor Services  
Baden-Wuertemberg-Hessen  
Frankfurt/Main, Germany

Fátima Nascimento MD  
Senior Consultant in Transfusion Medicine  
General Directorate of Health  
Lisbon, Portugal

Hitoshi Okazaki MD, PhD  
Senior Director  
Research and Development Department  
Central Blood Institute  
Blood Service Headquarters  
Japanese Red Cross Society  
Tokyo, Japan
List of Contributors

Hans-Ulrich Pfeiffer Dipl Biol
Production Manager
Institute for Transfusion Medicine and Immunohaematology
Clinics of the Johann Wolfgang Goethe University
Frankfurt/Main
German Red Cross Blood Donor Services
Baden-Wuerttemberg-Hessen
Frankfurt/Main, Germany

Constantina Politis MD
Associate Professor of Medicine
Athens University; Head of the Hellenic Coordinating Haemovigilance Centre (SKAE)
Athens, Greece

Simonetta Pupella MD
Responsible Medical Area, National Blood Centre
Istituto Superiore di Sanità
Rome, Italy

Philippe Renaudier MD, MS
French Society of Vigilance and Transfusion Therapeutics (SFVTT)
Regional Coordination of Hemovigilance
Agence Régionale de Santé Lorraine
Nancy, France

Martin R Schipperus MD, PhD
Hematologist
Head, Department of Hematology
Haga Teaching Hospital;
President, TRIP Dutch National Hemovigilance Office
The Hague, The Netherlands

Erhard Seifried MD, PhD
Professor of Transfusion Medicine
Chair for Transfusion Medicine and Immunohaematology
Medical Director and CEO
German Red Cross Blood Transfusion Service
Baden-Wuerttemberg—Hessen
Institute for Transfusion Medicine and Immunohaematology
JW Goethe University Frankfurt/Main
Frankfurt/Main, Germany

Walid Sireis MUDr
Head, Quality Management
Institute for Transfusion Medicine and Immunohaematology
Clinics of the Johann Wolfgang Goethe University
Frankfurt/Main
German Red Cross Blood Donor Services
Baden-Wuerttemberg-Hessen
Frankfurt/Main, Germany

Lisa J. Stevenson RN, Grad Dip Health Med Law, Cert Transfus Practice, Cert Crit Care
Transfusion Nurse Consultant
Blood Matters Program
Department of Health and Australian Red Cross Blood Service
Melbourne, Victoria, Australia

Paul F.W. Strengers MD, FFPM
Director, Medical Affairs and Product Development
Division of Plasma Products
Sanquin Blood Supply Foundation
Amsterdam, The Netherlands

D. Michael Strong PhD
Affiliate Professor
Department of Orthopaedics and Sports Medicine
University of Washington School of Medicine
Seattle, WA, USA

Kenji Tadokoro MD, PhD
Executive Officer
Blood Service Board of Management;
Director General
Central Blood Institute
Blood Service Headquarters
Japanese Red Cross Society
Tokyo, Japan

Clare Taylor PhD FRCP FRCPath
Consultant in Haematology and Transfusion Medicine
Former Medical Director of SHOT
c/o SHOT Office, Manchester Blood Centre
Manchester, UK

Dafydd Thomas MBChB, FRCA
Consultant in Intensive Care Medicine
Morriston Hospital
Swansea, Wales

Anita van Tilborgh-de Jong MD
Senior Hemovigilance Physician
TRIP Dutch National Hemovigilance Office
The Hague, The Netherlands

Peter Tomasulo MD
Chief Medical and Scientific Officer
Blood Systems Inc.
Scottsdale, AZ, USA

Tomislav Vuk MD
Specialist in Transfusion Medicine
Head of Quality Control and Quality Assurance Department
Croatian Institute of Transfusion Medicine
Zagreb, Croatia
Barbara I. Whitaker PhD
Director, Data and Special Programs
AABB
Bethesda, MD, USA

Johanna Wiersum-Osselton MD
National Coordinator
TRIP Dutch National Hemovigilance Office
The Hague, The Netherlands
and
Senior Donor Physician
Sanquin Blood Supply Foundation
Rotterdam, The Netherlands

Lorna M. Williamson BSc, MD, FRCP, FRCPath
Medical and Research Director
NHS Blood and Transplant
Watford, UK

Jeroen de Wit PharmD
Vice Chair, Executive Board
Sanquin Blood Supply Foundation
Amsterdam, The Netherlands

Erica M. Wood MBBS, FRACP, FRCPA
Consultant Haematologist
Chair, Serious Transfusion Incident Reporting (STIR) Expert Group
Blood Matters Program
Department of Health and Australian Red Cross Blood Service
and
Department of Clinical Haematology, Monash University
Melbourne, Victoria, Australia

Jun Wu MD, PhD
Blood Safety Surveillance and Health Care Acquired Infection Division
Public Health Agency of Canada
Ottawa, ON, Canada

Pauline Y. Zijlker-Jansen MD
Hemovigilance and Tissue Vigilance Physician
TRIP Dutch National Hemovigilance Office
The Hague, The Netherlands
Foreword

Hemovigilance is one of the most important activities for those of us who are active in the field of blood transfusion. Irrespective of your profession, whether blood banker, quality manager, donor physician, nurse, phlebotomist, laboratory technician, transfusing physician or hospital nurse, the safety of blood products from their “origin” in the blood donor until their use in the recipient is of utmost importance. The phrase “safety from vein to vein” was coined to illustrate the breadth of the field. Today, the field of hemovigilance is even more wide-ranging, covering blood components, tissues and cell preparations including donor vigilance, materiovigilance and safety of the patient.

While hemovigilance is well known to those who work in the field of transfusion medicine, there are important differences between countries when it comes to the implementation of national hemovigilance programs.

The International Hemovigilance Network (IHN) has done an excellent job in establishing common definitions and in bringing together the different national activities. Today in Europe, EU directives define our common standards in blood transfusion and similar approaches are taken in other regions of the world.

In June 2009, René de Vries, then President of the International Hemovigilance Network, was asked by Maria Khan, responsible for transfusion publications at Wiley-Blackwell, about the need for a handbook on hemovigilance that would outline and guide the reader on procedures of the transfusion chain. Maria asked René whether he believed such a book would be beneficial and, if so, who might make suitable editors and authors for the project.

The request from Wiley-Blackwell fell on fertile soil. After consultation with the IHN Board, René confirmed the need for such a book and moreover advised that the IHN Board had recently been discussing a similar idea. They were therefore willing to embark on the project. Finally, two IHN Board members agreed to take on the editorship of this book: René de Vries and Jean-Claude Faber.

_Hemovigilance: An Effective Tool for Improving Transfusion Safety_ is the first book on this subject and its aim is to become the textbook on hemovigilance. This may well be the case since all the ingredients to achieve this aim are present: the editors developed a master plan and communicated this to all the authors, gathering the best experts from all over the world. Contributors demonstrated their commitment, writing their chapters according to the uniform instructions and definitions set out by the editors. The book is as comprehensive as is possible for such a big subject and many diverse examples from different settings are given.

It not only provides clear-cut answers to the ‘Whats?’ and ‘Whys?’, but also to the ‘How do Is?’ Examples of national and international hemovigilance systems and a summary of past achievements as well as new developments and future challenges will help readers to integrate their local or national experience into the global scheme.

We are very pleased with the new hemovigilance book and we hope that many readers from both within the field of transfusion medicine and from other fields such as quality and safety management, and regulatory affairs, will enjoy it. We are confident that _Hemovigilance: An Effective Tool for Improving Transfusion Safety_ will contribute to the improvement of safety and quality of blood transfusion.

Erhard Seifried* and Markus M. Mueller
Frankfurt/Main, Germany
March 2012

*past president of the International Society for Blood Transfusion (ISBT).